Cookie Hinweis

Wir verwenden Cookies, um Ihnen ein optimales Webseiten-Erlebnis zu bieten. Dazu zählen Cookies, die für den Betrieb der Seite notwendig sind, sowie solche, die lediglich zu anonymen Statistikzwecken, für Komforteinstellungen oder zur Anzeige personalisierter Inhalte genutzt werden. Sie können selbst entscheiden, welche Kategorien Sie zulassen möchten. Bitte beachten Sie, dass auf Basis Ihrer Einstellungen womöglich nicht mehr alle Funktionalitäten der Seite zur Verfügung stehen. Weitere Informationen finden Sie in unseren Datenschutzhinweisen .

Essentiell

Diese Cookies sind für die Funktionalität unserer Website erforderlich und können nicht deaktiviert werden.

Name Webedition CMS
Zweck Dieses Cookie wird vom CMS (Content Management System) Webedition für die unverwechselbare Identifizierung eines Anwenders gesetzt. Es bietet dem Anwender bessere Bedienerführung, z.B. Speicherung von Sucheinstellungen oder Formulardaten. Typischerweise wird dieses Cookie beim Schließen des Browsers gelöscht.
Name econda
Zweck Session-Cookie für die Webanalyse Software econda. Diese läuft im Modus „Anonymisiertes Messen“.
Statistik

Diese Cookies helfen uns zu verstehen, wie Besucher mit unserer Webseite interagieren, indem Informationen anonym gesammelt und analysiert werden. Je nach Tool werden ein oder mehrere Cookies des Anbieters gesetzt.

Name econda
Zweck Measure with Visitor Cookie emos_jcvid
Externe Medien

Inhalte von Videoplattformen werden standardmäßig blockiert. Wenn Cookies von externen Medien akzeptiert werden, bedarf der Zugriff auf diese Inhalte keiner manuellen Zustimmung mehr.

Name Youtube
Zweck Externe Medien

Publikationen

1.  Afshar-Oromieh,A., Wolf,M., Haberkorn,U., Kachelriess,M., Gnirs,R., Kopka,K., Schlemmer, HP., Freitag, MT.: Effects of arm truncation on the appearance of the halo artifact in 68Ga-PSMA-11 (HBED-CC) PET/MRI. European Journal of Nuclear Medicine and Molecular Imaging 44 (10), 1636-1646, 2017.

2.  Afshar-Oromieh,A., Sattler, LP., Mier,W., Hadaschik,BA., Debus,J., Holland-Letz,T., Kopka,K., Haberkorn,U.: The Clinical Impact of Additional Late PET/CT Imaging with 68Ga-PSMA-11 (HBED-CC) in the Diagnosis of Prostate Cancer. Journal of Nuclear Medicine 58 (5), 750-755, 2017.

3.  Afshar-Oromieh,A., Haberkorn,U., Zechmann,C., Armor,T., Mier,W., Spohn,F., Debus,N., Holland-Letz,T., Babich,J., Kratochwil,C.: Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with 131I-MIP-1095. European Journal of Nuclear Medicine and Molecular Imaging 44 (6), 950-959, 2017.

4.  Afshar-Oromieh,A., Holland-Letz,T., Giesel,F.L., Kratochwil,C., Mier,W., Haufe,S., Debus,N., Eder,M., Eisenhut,M., Schäfer,M., Neels,O., Hohenfellner,M., Kopka,K., Kauczor,H.U., Debus,J., Haberkorn,U.: Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. European Journal of Nuclear Medicine and Molecular Imaging 44 (8), 1258-1268, 2017.

5.  Afshar-Oromieh A, Holland-Letz T, Giesel FL, Kratochwil C, Mier W, Haufe S, Debus N, Eder M, Eisenhut M, Schaefer M, Neels O, Hohenfellner M, Kopka K, Kauczor HU, Debus J, Haberkorn U: CORRECTION: Diagnostic performance of Ga-68-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients (vol 44, pg 1258, 2017). European Journal of Nuclear Medicine and Molecular Imaging 44 (10), 1781-1781, 2017.  

6.  Altmann,A., Sauter,M., Roesch,S., Mier,W., Warta,R., Debus,J., Dyckhoff,G., Herold-Mende,C., Haberkorn,U.: Identification of a Novel ITG alpha(v)beta(6)-Binding Peptide Using Protein Separation and Phage Display. Clinical Cancer Research 23 (15), 4170-4180, 2017.

7.  Anwar,H., Sachpekidis,C., Schwarzbach,M., Dimitrakopoulou-Strauss,A.: Fluorine-18-FDG PET/CT in a patient with angiomyolipoma: Response to mammalian target of rapamycin inhibitor therapy. Hellenic Journal of Nuclear Medicine 20 (2), 169-171, 2017.

8.  Baranski,A.C., Schäfer,M., Bauder-Wüst,U., Wacker,A., Schmidt,J., Liolios,C., Mier,W., Haberkorn,U., Eisenhut,M., Kopka,K., Eder,M.: Improving the Imaging Contrast of 68Ga-PSMA-11 by Targeted Linker Design: Charged Spacer Moieties Enhance the Pharmacokinetic Properties. Bioconjugate Chemistry 28 (9), 2485-2492, 2017.

9.  Cardinale,J., Schäfer,M., Benešová,M., Bauder-Wüst,U., Leotta,K., Eder,M., Neels,O.C., Haberkorn,U., Giesel,F.L., Kopka,K.: Preclinical Evaluation of F-18-PSMA-1007, a New Prostate-Specific Membrane Antigen Ligand for Prostate Cancer Imaging. Journal of Nuclear Medicine 58 (3), 425-431, 2017.

10. Dimitrakopoulou-Strauss,A., Ronellenfitsch,U., Cheng,C., Pan,L., Sachpekidis,C., Hohenberger,P., Henzler,T.: Imaging therapy response of gastrointestinal stromal tumors (GIST) with FDG PET, CT and MRI: a systematic review. Clinical and Translation Imaging 5 (3), 183-197, 2017.

11.  Fendler,W.P., Eiber,M., Beheshti,M., Bomanji,J., Ceci,F., Cho,S., Giesel,F., Haberkorn,U., Hope,T.A., Kopka,K., Krause,B.J., Mottaghy,F.M., Schoeder,H., Sunderland,J., Wan,S., Wester,H.J., Fanti,S., Herrmann,K.: 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. European Journal of Nuclear Medicine and Molecular Imaging 44 (6), 1014-1024, 2017.

12.  Flechsig,P., Frank,P., Kratochwil,C., Antoch,G., Rath,D., Moltz,J., Rieser,M., Warth,A., Kauczor,HU., Schwartz,LH., Haberkorn,U., Giesel,FL.: Radiomic Analysis using Density Threshold for FDG-PET/CT-Based N-Staging in Lung Cancer Patients. Molecular Imaging and Biology 19 (2), 315-322, 2017.

13.  Freitag, M.T., Fenchel, M., Bäumer, P., Heußer, T., Rank, C.M., Kachelrieß, M., Paech, D., Kopka, K., Bickelhaupt, S., Dimitrakopoulou-Strauss, A., Maier-Hein, K., Floca, R., Ladd, M.E., Schlemmer, H.P., Maier, F.: Improved clinical workflow for simultaneous whole-body PET/MRI using high-resolution CAIPIRINHA-accelerated MR-based attenuation correction. European Radiology 96, 12-20, 2017.

14.  Freitag, M.F., Radtke, J.P., Afshar-Oromieh, A., Roethke, M.C., Hadaschik, B.A., Gleave, M., Bonekamp, D., Kopka, K., Eder, M., Heusser, T., Kachelriess, M., Wieczorek, K., Sachpekidis, C., Flechsig, P., Giesel, F., Hohenfellner, M., Haberkorn, U., Schlemmer, H.P., Dimitrakopoulou-Strauss, A.: Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in 68Ga-PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI integrated in simultaneous PET/MRI. European Journal of Nuclear Medicine and Molecular Imaging 44 (5), 776-787, 2017.

15.  Gasch,C., Düwel,C., Kopka,K., Kratochwil,C., Vinsensia,M., Eiber,M., Maurer,T., Haberkorn,U., Hadaschik,B., Giesel,F.L.: Significance of PSMA imaging in prostate cancer. Urologe / A 56 (1), 3-12, 2017.

16.  Giammarile F, Muylle K, Delgado Bolton R, Kunikowska J, Haberkorn U, Oyen W: Dosimetry in clinical radionuclide therapy: the devil is in the detail. European Journal of Nuclear Medicine and Molecular Imaging 44 (12), 1-3, 2017.

17.  Giesel FL, Schneider F, Kratochwil C, Rath D, Moltz J, Holland-Letz T, Kauczor HU, Schwartz LH, Haberkorn U, Flechsig P: Correlation Between SUVmax and CT Radiomic Analysis Using Lymph Node Density in PET/CT-Based Lymph Node Staging. Journal of Nuclear Medicine 58 (2), 282-287, 2017.

18.  Giesel,F.L., Hadaschik,B., Cardinale,J., Radtke,J., Vinsensia,M., Lehnert,W., Kesch,C., Tolstov,Y., Singer,S., Grabe,N., Duensing,S., Schäfer,M., Neels,O.C., Mier,W., Haberkorn,U., Kopka,K., Kratochwil,C.: F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. European Journal of Nuclear Medicine and Molecular Imaging 44 (4), 678-688, 2017.

19.  Giesel,F.L., Kesch,C., Yun,M., Cardinale,J., Haberkorn,U., Kopka,K., Kratochwil,C., Hadaschik,B.A.: 18F-PSMA-1007 PET/CT Detects Micrometastases in a Patient With Biochemically Recurrent Prostate Cancer. Clinical Genitourinary Cancer 15 (3), e497-e499, 2017.

20.  Haberkorn,U., Mier W, Kopka K, Herold-Mende C, Altmann A, Babich J: Identification of Ligands and Translation to Clinical Applications. Journal of Nuclear Medicine 58 (Suppl 2), 27S-33S, 2017.

21.  Haberkorn,U., Giesel F, Morgenstern A, Kratochwil C: The Future of Radioligand Therapy: alpha, beta, or Both?. Journal of Nuclear Medicine 58 (7), 1017-1018, 2017.

22.  Haberkorn,U., Giesel,F., Kopka,K., Kratochwil,C.: Radiotherapy with PSMA ligands in prostate cancer. Medecine Nucleaire-Imagerie Fonctionnelle et Metabolique 41 (3), 232-234, 2017.

23.  Hassel,JC., Jiang,H., Bender,C., Winkler,J., Sevko,A., Shevchenko,I., Halama,N., Dimitrakopoulou-Strauss,A., Haefeli,WE., Jaeger,D., Enk,A., Utikal,J., Umansky,V.: Tadalafil has biologic activity in human melanoma. Results of a pilot trial with Tadalafil in patients with metastatic Melanoma (TaMe). OncoImmunology 6 (9), e1326440, 2017.

24.  Heusser,T., Mann,P., Rank,C.M., Schaefer,M., Dimitrakopoulou-Strauss,A., Schlemmer,H.P., Hadaschik,B.A., Kopka,K., Bachert,P., Kachelriess,M., Freitag,M.T.: Investigation of the halo-artifact in Ga-68-PSMA-11-PET/MRI. PLoS ONE 12 (8), e0183329, 2017.

25.  Hoffend,J., Sachpekidis,C., Dimitrakopoulou-Strauss,A.: [Response evaluation in nuclear medicine : Criteria, results and pitfalls]. Radiologe 57 (10), 834-839, 2017.

26.  Kasper,B., Gruenwald,V., Reichardt,P., Bauer,S., Rauch,G., Limprecht,R., Sommer,M., Dimitrakopoulou-Strauss,A., Pilz,L., Haller,F., Hohenberger,P.: Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG). European Journal of Cancer 76, 60-67, 2017.

27.  Kesch,C., Kratochwil,C., Mier,W., Kopka,K., Giesel,F.L.: Ga-68 or F-18 for Prostate Cancer Imaging. Journal of Nuclear Medicine 58 (5), 687-688, 2017.

28.  Kesch,C., Vinsensia,M., Radtke,J.P., Schlemmer,H.P., Heller,M., Ellert,E., Holland-Letz,T., Duensing,S., Grabe,N., Afshar-Oromieh,A., Wieczorek,K., Schäfer,M., Neels,O.C., Cardinale,J., Kratochwil,C., Hohenfellner,M., Kopka,K., Haberkorn,U., Hadaschik,B.A., Giesel,F.L.: Intra-individual comparison of 18F-PSMA-1007-PET/CT, multi-parametric MRI and radical prostatectomy specimen in patients with primary prostate cancer - a retrospective, proof of concept study. Journal of Nuclear Medicine 58 (11), 1805-1810, 2017.

29.  Koerber SA, Utzinger MT, Kratochwil C, Kesch C, Haefner MF, Katayama S, Mier W, Iagaru AH, Herfarth K, Haberkorn U, Debus J, Giesel FL: (68)Ga-PSMA-11 PET/CT in Newly Diagnosed Carcinoma of the Prostate: Correlation of Intraprostatic PSMA Uptake with Several Clinical Parameters. Journal of Nuclear Medicine 58 (12), 1943-1948, 2017.

30.  Kopka K, Benesova M, Barinka C, Haberkorn U, Babich J: Glu-Ureido-Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers. Journal of Nuclear Medicine 58 (Suppl 2), 17S-26S, 2017.

31.  Kratochwil C, Bruchertseifer F, Rathke H, Bronzel M, Apostolidis C, Weichert W, Haberkorn U, Giesel FL, Morgenstern A: Targeted alpha-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding. Journal of Nuclear Medicine 58 (10), 1624-1631, 2017.

32.  Loktev,A., Haberkorn,U., Mier,W.: Multicyclic Peptides as Scaffolds for the Development of Tumor Targeting Agents. Current Medicinal Chemistry 24 (20), 2141-2155, 2017.

33.  Nientiedt C, Tolstov Y, Volckmar AL, Endris V, Bonekamp D, Haberkorn U, Jäger D, Sültmann H, Stenzinger A, Hohenfellner M, Grüllich C, Duensing S: PARP inhibition in BRCA2-mutated prostate cancer. Annals of Oncology 28 (1), 189-191, 2017.

34.  Paech, D., Giesel, F.L., Unterhinninghofen, R., Schlemmer, H.P., Kuner, T., Doll, S.: Cadaver-specific CT Scans Visualized at the Dissection Table Combined with Virtual Dissection Tables Improve Learning Performance in General Gross Anatomy. European Radiology 27 (5), 2153-2160, 2017.

35.  Pan,L., Cheng,C., Haberkorn,U., Dimitrakopoulou-Strauss,A.: Machine learning-based kinetic modeling: a robust and reproducible solution for quantitative analysis of dynamic PET data. Physics in Medicine and Biology 62 (9), 3566-3581, 2017.

36.  Petersen LJ, Nielsen JB, Dettmann K, Fisker RV, Haberkorn U, Stenholt L, Zacho HD: 68Ga-PSMA PET/CT for the detection of bone metastasis in recurrent prostate cancer and a PSA level

37.  Pushkarevskaya,A., Neuberger,U., Dimitrakopoulou-Strauss,A., Enk,A., Hassel,JC.: Severe Ocular Myositis After Ipilimumab Treatment for Melanoma: A Report of 2 Cases. Journal of Immunotherapy 40 (7), 282-285, 2017.

38.  Rahbar,K., Ahmadzadehfar,H., Kratochwil,C., Haberkorn,U., Schäfers,M., Essler,M., Baum,R.P., Kulkarani,H.R., Schmidt,M., Bartenstein,P., Pfestroff,A., Lützen,U., Marx,M., Prasad,V., Brenner,W., Heinzel,A., Ruf,J., Meyer,P.T., Heuschkel,M., Eveslage,M., Bögemann,M., Fendler,W.P., Krause,B.J.: German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. Journal of Nuclear Medicine 58 (1), 85-90, 2017.

39.  Sachpekidis, C., Hillengass, J., Goldschmidt, H., Anwar, H., Haberkorn, U., Dimitrakopoulou-Strauss, A.: Quantitative analysis of 18F-NaF dynamic PET/CT cannot differentiate malignant from benign lesions in multiple myeloma. American Journal of Nuclear Medicine and Molecular Imaging 7 (4), 148-156, 2017.

40.  Sachpekidis,C., Hillengass,J., Goldschmidt,H., Wagner,B., Haberkorn, U., Kopka,K., Dimitrakopoulou-Strauss,A.: Treatment response evaluation with 18F-FDG PET/CT and 18F-NaF PET/CT in multiple myeloma patients undergoing high-dose chemotherapy and autologous stem cell transplantation. European Journal of Nuclear Medicine and Molecular Imaging 44 (1), 50-62, 2017.

41.  Schwarzenboeck SM, Rauscher I, Bluemel C, Fendler WP, Rowe SP, Pomper MG, Asfhar-Oromieh A, Herrmann K, Eiber M: PSMA Ligands for PET Imaging of Prostate Cancer. Journal of Nuclear Medicine 58 (10), 1545-1552, 2017.

42.  Stahl,V., Maier,F., Freitag,M.T., Floca,R.O., Berger,M.C., Umathum,R., Berriel Diaz,M., Herzig,S., Weber,M.A., Dimitrakopoulou-Strauss,A., Rink,K., Bachert,P., Ladd,M.E., Nagel,A.M.: In vivo assessment of cold stimulation effects on the fat fraction of brown adipose tissue using DIXON MRI. Journal of Magnetic Resonance Imaging 45 (2), 369-380, 2017.

43.  Vinsensia,M., Choyke,P.L., Hadaschik,B., Holland-Letz,T., Moltz,J., Kopka,K., Rauscher,I., Mier,W., Schwaiger,M., Haberkorn,U., Maurer,T., Kratochwil,C., Eiber,M., Giesel,F.: 68Ga-PSMA PET/CT and volumetric morphology of PET-positive lymph nodes stratified by tumor differentiation of prostate cancer. Journal of Nuclear Medicine 58 (12), 1949-1955, 2017.

44.  Will,L., Sonni,I., Kopka,K., Kratochwil,C., Giesel,F.L., Haberkorn,U.: Radiolabeled prostate-specific membrane antigen small-molecule inhibitors. Quarterly Journal of Nuclear Medicine and Molecular Imaging 61 (2), 168-180, 2017.

45.  Winkler, J.K., Dimitrakopoulou-Strauss,A., Sachpekidis,C., Enk,A., Hassel,J.C.: Ipilimumab has efficacy in metastatic Merkel cell carcinoma: a case series of five patients. Journal of the European Academy of Dermatology and Venereology 31 (9), e389-e391, 2017.

46.  Winkler,JK., Buder-Bakhaya,K., Dimitrakopoulou-Strauss,A., Enk,A., Hassel,JC.: [Malignant melanoma: Current status]. Radiologe 57 (10), 814-821, 2017.

 

nach oben
powered by webEdition CMS